Parkinson’s disease (PD) is a multifactorial neurodegenerative disorder with high prevalence among the elderly, primarily manifested by progressive decline in motor function. The aging global demographic and increased life expectancy have led to a rapid surge in PD cases, imposing a significant societal burden. PD along with other neurodegenerative diseases has garnered increasing attention from the scientific community. In PD, motor symptoms are recognized when approximately 60% of dopaminergic neurons have been damaged. The irreversible feature of PD and benefits of early intervention underscore the importance of disease onset prediction and prompt diagnosis. The advent of digital health technology in recent years has elevated the role of digital biomarkers in precisely and sensitively detecting early PD clinical symptoms, evaluating treatment effectiveness, and guiding clinical medication, focusing especially on motor function, responsiveness and sleep quality assessments. This review examines prevalent digital biomarkers for PD and highlights the latest advancements.

帕金森病（PD）是一种多因素神经退行性疾病，在老年人中发病率较高，主要表现为运动功能进行性衰退。全球人口老龄化和预期寿命的延长导致帕金森病病例迅速激增，造成了巨大的社会负担。 PD 与其他神经退行性疾病一起引起了科学界越来越多的关注。在 PD 中，当大约 60% 的多巴胺能神经元受损时，就会出现运动症状。 PD 的不可逆特征和早期干预的益处强调了疾病发作预测和及时诊断的重要性。近年来数字健康技术的出现，提升了数字生物标志物在精准灵敏检测帕金森病早期临床症状、评估治疗效果、指导临床用药等方面的作用，尤其关注运动功能、反应能力和睡眠质量评估。这篇综述研究了流行的帕金森病数字生物标志物，并重点介绍了最新进展。